Fibronectin binding domains with reduced immunogenicity
US-9416170-B2 · Aug 16, 2016 · US
US10065987B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10065987-B2 |
| Application number | US-201414766848-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 11, 2014 |
| Priority date | Feb 12, 2013 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are methods for refolding denatured protein (e.g., from inclusion bodies) that do not require the use of a denaturing agent. Exemplary methods use a high pH for solubilizing denatured protein, followed by a decrease in pH for refolding the proteins.
Opening claim text (preview).
The invention claimed is: 1. A method for refolding a denatured protein, comprising suspending a denatured protein in a suspension solution to obtain a composition comprising suspended denatured proteins; combining the composition comprising suspended denatured proteins with a solubilization buffer having a pH in the range of 11.5 to 12.8 to thereby obtain a composition comprising solubilized denatured proteins; and combining the composition comprising solubilized denatured proteins with a refold buffer having a pH in the range of 10 to 10.9 to thereby obtain a composition comprising refolded proteins; wherein the method does not include the use of a denaturing agent. 2. The method of claim 1 , wherein the suspension solution consists of water. 3. The method of claim 1 , wherein the denatured proteins are suspended in suspension solution at a ratio of weight (g) of denatured proteins:volume (ml) of suspension solution of 1:1-3. 4. The method of claim 1 , wherein the composition comprising suspended denatured proteins is combined with solubilization buffer at a ratio of weight (g) of denatured proteins:volume (ml) of solubilization buffer of 1:10-30. 5. The method of claim 1 , wherein the composition comprising solubilized denatured proteins is combined with refold buffer at a ratio of volume of solubilization buffer:volume of refold buffer of 1:1-5. 6. The method of claim 1 , wherein the denatured proteins are suspended in suspension solution at a ratio of weight (g) of denatured proteins:volume (ml) of suspension solution of 1:1-3; the composition comprising suspended denatured proteins is combined with solubilization buffer at a ratio of weight (g) of denatured proteins:volume (ml) of solubilization buffer of 1:10-30; and the composition comprising solubilized denatured proteins is combined with refold buffer at a ratio of volume of solubilization buffer:volume of refold buffer of 1:1-5. 7. The method of claim 1 , wherein the suspended denatured proteins and the solubilization buffer are combined for 1-10 minutes prior to being combined with the refold buffer. 8. The method of claim 1 , wherein the composition comprising the solubilized denatured proteins is combined with the refold buffer for 5-60 minutes. 9. The method of claim 1 , wherein the solubilization buffer comprises Arginine. 10. The method of claim 1 , wherein the refold buffer comprises Arginine. 11. The method of claim 1 , wherein the refold buffer comprises an oxidizing agent. 12. The method of claim 1 , wherein the method does not comprise first suspending the denatured protein in a suspension solution. 13. The method of claim 1 , wherein the denatured proteins are in the form of inclusion bodies (IBs). 14. The method of claim 1 , wherein the protein comprises an Fc region. 15. The method of claim 14 , wherein the protein comprises a binding domain that specifically binds to a target protein, and wherein the binding domain is an alternative scaffold binding domain. 16. The method of claim 15 , wherein the alternative scaffold binding domain is a fibronectin based scaffold domain.
having a known sequence of two or more amino acids, e.g. glutathione · CPC title
by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents · CPC title
by redox-reactions involving cystein/cystin side chains · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
containing domain for protein-protein interaction · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.